Novo Nordisk is paying $300 million upfront for rights to a molecule that has never dosed a human outside of China, a bet that reflects how far companies will go to own the next generation of oral GLP-1 therapies. The asset, HRS-1596 from Hengrui Pharma, is a GLP-1 and GIP dual receptor agonist designed for once-weekly oral dosing, and the total deal value reaches up to $2.6 billion if development, regulatory, and commercial milestones are hit. Hengrui also retains royalties on net sales in Novo’s licensed territory, which covers everything outside mainland China, Hong Kong, Macao, and Taiwan.
The clinical rationale is straightforward: current approved injectable GLP-1 therapies like semaglutide and tirzepatide require weekly subcutaneous injections, and patients on those regimens must manage needle administration indefinitely. HRS-1596 targets appetite suppression, insulin secretion, and insulin sensitivity through its dual mechanism, with obesity, type 2 diabetes, and broader metabolic disease as intended indications. Hengrui has already received Chinese regulatory clearance to start Phase I trials for weight management and type 2 diabetes, making this a pre-data transaction. Novo is licensing a preclinical-to-Phase-I asset and absorbing the full development risk in every major market outside China.
The structure tells you something about Novo’s pipeline strategy. Oral peptide delivery is technically difficult, and Novo has its own oral semaglutide program. Acquiring external dual-agonist candidates at the earliest possible stage, before Phase I data resets price expectations upward, lets Novo build optionality without waiting to see whose formulation chemistry performs best. The $300 million upfront on a Phase I-ready asset is a large number for that stage, suggesting Novo’s assessment of HRS-1596’s oral bioavailability profile is already favorable, though no Phase I human data yet exists to confirm that.
The deal closes after U.S. Hart-Scott-Rodino antitrust clearance, expected in the fourth quarter of 2026. The first concrete signal worth tracking is the Phase I readout from Hengrui’s China trial: if early pharmacokinetic data on oral absorption holds up, that will either validate the $2.6 billion ceiling or expose how much of this deal is structural option rather than conviction.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
